Key points are not available for this paper at this time.
Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Rini et al. (Sat,) studied this question.